Novo Nordisk's 'CagriSema' Achieves Greater Weight Loss Compared to 'Tirzepatide' - Sarmad
Novo Nordisk announced today the preliminary results from the Phase 3 trials of REIMAGINE 5 and REDEFINE 9, which evaluated cagrilintide and semaglutide (cagrisema), the company’s new investigational once-weekly treatment for weight management and type 2 diabetes. The key findings were presented at Novo Nordisk’s Capital Markets Day investor meeting.
In the REIMAGINE 5 study, cagrisema 1.0 mg/1.0 mg demonstrated superior weight loss compared to tirzepatide 5 mg, achieving an average reduction of 12.4% versus 9.1% with tirzepatide. Cagrisema also lowered HbA1c by 1.71%, a reduction comparable to the 1.67% observed with tirzepatide.
In the REDEFINE 9 study, cagrisema 1.0 mg/1.0 mg resulted in a 21.0% weight loss compared to 2.0% with placebo, thereby meeting its primary endpoint of demonstrating efficacy. Cagrisema also showed greater improvements than placebo in prespecified secondary endpoints, including systolic blood pressure, waist-to-height ratio, and fasting lipid profile.
Martin Holst Lang, Executive Vice President, Chief Scientific Officer, and Head of Research and Development at Novo Nordisk, said: “The results for cagrisema are encouraging, confirming the efficacy of the semaglutide and cagrilintide combination. Even at the 1.0 mg/1.0 mg dose, cagrisema achieved greater weight loss than tirzepatide 5 mg, along with impressive outcomes related to obesity and type 2 diabetes management. Cagrisema remains an investigational treatment, but these results reinforce our confidence in its potential, add to the growing body of evidence on the role of the amylin component, and renew our commitment to developing the next generation of obesity and type 2 diabetes therapies.”
Decisions regarding the management of obesity and type 2 diabetes are typically influenced by individual patient needs, and not all patients receive the maximum treatment dose. These data provide important insights into the potential of cagrisema 1.0 mg/1.0 mg and expand our understanding of efficacy, safety, tolerability, and dose flexibility in serving individual patients.
